Solutions for Radiochemicals

UHE Experts Visit Huayi Technology to Deepen Collaboration in Radiopharmaceuticals

Dr. Michael Nader, head of the Radiopharmacy Department at University Hospital Essen, is widely recognized for his extensive expertise in the development, production, and clinical application of radiopharmaceuticals. Dr. Fadi Zarrad also plays a pivotal role in the department, making significant contributions to advancing radiopharmaceutical research and operations.Accompanied by Huayi team, Dr. Nader and Dr. Zarrad toured Huayi’s radiopharmaceutical R&D center, GMP-compliant production facilities, and quality control laboratories, gaining a comprehensive understanding of Huayi’s capabilities in the full-cycle development and standardized production of radiopharmaceuticals. Both experts were highly impressed by Huayi’s technological strength and rapid progress in the field.

Huayi Technology at iSRS 2025

From May 11th to 15th, 2025, the renowned iSRS 2025 was grandly held in Gold Coast, Australia. Jiangsu Huayi Technology Co., Ltd. (hereinafter referred to as “Huayi Technology”) was honored to participate in this momentous event, gathering together with experts and leaders in the international field of radiation research to jointly explore the latest frontiers of radiation research.

Huayi Isotopes Achieves FDA DMF Acceptance for DOTATATE ACETATE

Huayi Isotopes, a subsidiary of Huayi Technology Co., Ltd., has received a Drug Master File (DMF) acceptance letter from the U.S. Food and Drug Administration (FDA) for its DOTATATE ACETATE (DMF No. 041558), a peptide-based precursor for radiopharmaceuticals.

Huayi Pharmaceutical (Guangdong) Co., Ltd. Obtains Radioactive Pharmaceutical Production License

Huayi Pharmaceutical (Guangdong) Co., Ltd. successfully obtained the “Radioactive Pharmaceutical Production License” issued by the National Medical Products Administration.

HIC at 2025 ALASBIMN: Exploring Frontiers in Nuclear Medicine & Molecular Imaging